CytomX Therapeutics has been granted a patent for their invention of antibodies that bind to CD166, as well as activatable antibodies that specifically bind to CD166. These antibodies can be used in various therapeutic, diagnostic, and prophylactic applications for treating disorders or diseases associated with CD166-expressing cells. The patent also covers the specific amino acid sequences of the antibodies and their conjugation with masking and cleavable moieties. GlobalData’s report on CytomX Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights CytomX Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on CytomX Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. CytomX Therapeutics's grant share as of September 2023 was 29%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for activatable antibodies that bind cd166

Source: United States Patent and Trademark Office (USPTO). Credit: CytomX Therapeutics Inc

A recently granted patent (Publication Number: US11753466B2) describes a method for treating, alleviating symptoms of, or delaying the progression of a disorder or disease associated with cells expressing CD166. The method involves administering a therapeutically effective amount of a conjugated activatable antibody that binds to CD166 when activated. The activatable antibody consists of an antibody or antigen binding fragment that specifically binds to mammalian CD166, including human CD166 and cynomolgus monkey CD166. The antibody is conjugated to an agent, which can have various characteristics such as being a toxin, microtubule inhibitor, nucleic acid damaging agent, or a diagnostic agent. The conjugated activatable antibody also includes a masking moiety that inhibits the binding of the antibody to CD166 when in an uncleaved state, and a cleavable moiety coupled to the antibody that functions as a substrate for a protease.

The patent claims cover the use of the method for treating various disorders and diseases associated with CD166-expressing cells, including different types of cancer such as adenocarcinoma, breast cancer (including Her2-negative and estrogen receptor-positive breast cancer), triple-negative breast cancer (TNBC), lung cancer, leukemia, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, and many others. The patent also describes specific amino acid sequences for the antibody's variable regions and masking moiety, as well as different combinations of amino acid sequences for the activatable antibody.

The method involves administering the conjugated activatable antibody to a subject in a therapeutically effective amount, where the antibody specifically binds to CD166 on diseased cells. The conjugated activatable antibody can be administered in various pharmaceutical compositions, which include the antibody and a carrier.

This patent provides a novel approach for targeting CD166-expressing cells in the treatment of various disorders and diseases, particularly cancer. The use of an activatable antibody allows for specific binding to CD166 when activated, potentially reducing off-target effects. The conjugation of an agent to the antibody provides additional therapeutic benefits, such as delivering toxins or diagnostic agents directly to the diseased cells. The patent's claims cover a wide range of applications and provide specific amino acid sequences for the antibody and masking moiety, allowing for potential development of targeted therapies based on this technology.

To know more about GlobalData’s detailed insights on CytomX Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies